Withdrawn before it began

BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy

NCT05363644 · AdventHealth · Updated 29 June 2023

What is being tested: BioDFence G3
For: Prostate Cancer; Prostatectomy; Erectile Dysfunction Following Radical Prostatectomy; Incontinence, Urinary
Kind of study: Tests a treatment or device on volunteers. Phase 3.
Who can join: Ages 40 years to 70 years. The full rules are on the registry page.
Where: United States
When: Starts or started 1 April 2023, ends 30 June 2024. Registered 6 May 2022.
Results: None posted yet.

In the researchers' words

The purpose of this study is to assess functional outcomes post operatively after the use of BioDFence® G3 during robotic radical prostatectomy.

Sites